Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease
- PMID: 32383278
- DOI: 10.1111/apt.15766
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease
Abstract
Background: Insufficient data exist for peristomal pyoderma gangrenosum (PPG), which primarily affects patients with inflammatory bowel disease (IBD).
Aims: To evaluate the risk factors and treatment response of PPG in IBD patients in a real-life cohort.
Methods: Cases of PPG were identified retrospectively using ICD-9/10 codes in patients with IBD who had an ostomy at a tertiary care centre. Disease-specific characteristics were compared between groups with and without PPG, and response to therapy was evaluated in patients with PPG.
Results: The cohort included 41 IBD patients with PPG and 123 IBD controls with an ostomy who never developed PPG. Patients with PPG were more likely to be female (76% vs 51%, P = 0.006), had higher BMIs (29.78 ± 0.89 vs 23.53 ± 0.51, P < 0.0001) and had increased usage of pouch belts (97% vs 71%, P = 0.0008) compared to controls. There were no differences in age at surgery (41.76 ± 2.60 vs 43.49 ± 1.50, P = 0.57) or IBD diagnosis (63% vs 54% Crohn's disease, P = 0.28) between PPG and controls. 85% of PPG patients achieved complete resolution with different treatments, including surgery. Complete resolution with topical corticosteroids and calcineurin inhibitors alone were low (14% and 13% respectively). Higher rates of complete resolution were reported with anti-tumour necrosis factor (TNF) agents (63%) and surgical interventions (80%).
Conclusions: Female gender, higher BMI and pouch belts were associated with increased risk of developing PPG. Most PPG cases resolved after treatment with the highest rates of complete resolution seen with anti-TNF agents and surgical intervention.
© 2020 John Wiley & Sons Ltd.
Comment in
-
Editorial: peristomal pyoderma gangrenosum-a challenge for patients, healthcare professionals and research.Aliment Pharmacol Ther. 2020 Jul;52(2):404-405. doi: 10.1111/apt.15822. Aliment Pharmacol Ther. 2020. PMID: 32592244 No abstract available.
References
REFERENCES
-
- Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-585.
-
- Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008-1017.
-
- Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281-293.
-
- Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:568-569; discussion 568-569.
-
- Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA. 2000;284:1546-1548.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources